VE-Cadherin: The Gatekeeper of Blood Vessels

VE-cadherin is the single most important adhesion protein holding the cells of your blood vessel walls together. Found exclusively on the endothelial cells that line every artery, vein, and capillary in your body, it forms molecular zippers between neighboring cells, controlling what gets out of the bloodstream and what stays in. When VE-cadherin works properly, the vascular lining is selective and tight; when it is disrupted, fluid leaks into tissues, immune responses spiral, and diseases from sepsis to cancer gain an advantage. The nickname “gatekeeper” is well earned, but it undersells the range of jobs this protein actually performs.

How VE-Cadherin Holds the Vessel Wall Together

Endothelial cells are arranged like tiles across the inner surface of every blood vessel. The gaps between those tiles are sealed by adherens junctions, and VE-cadherin is the structural backbone of those junctions. Each VE-cadherin molecule extends outward from one endothelial cell, and its outermost region links up with a VE-cadherin molecule projecting from the neighboring cell. Crystallography work resolved this binding region at high resolution and showed that the connection forms through a “strand-swap” mechanism: a short segment of one molecule slots into a pocket on its partner, and vice versa, creating a stable but reversible bond between the two cells.¹

On the inside of the cell, VE-cadherin does not float freely in the membrane. Its cytoplasmic tail connects to a network of intracellular proteins, including a family of molecules called catenins, which in turn anchor the whole assembly to the actin cytoskeleton, the scaffolding that gives cells their shape and mechanical strength. This connection can be direct or can involve linker proteins such as vinculin and alpha-actinin.² The practical effect is that each junction is both a glue holding cells together and a tension-bearing cable tied into the mechanical framework of the vessel wall. That dual role turns out to matter a great deal for how the body senses blood flow, as well as for what goes wrong in disease.

Letting Immune Cells Through Without Breaking the Seal

One of the most impressive tricks of VE-cadherin is how it handles immune-cell traffic. When you get an infection or injury, white blood cells need to leave the bloodstream and enter the surrounding tissue. They do this by squeezing between endothelial cells, a process called transmigration. It sounds destructive, but the vessel wall manages it with surprisingly little collateral damage.

Live-imaging studies have captured this in real time. As a white blood cell arrives at a junction, VE-cadherin does not simply disappear or break apart. Instead, it is physically pushed aside, relocating to different ends of the transmigration site while the immune cell passes through.³ Additional imaging using fluorescently tagged VE-cadherin showed that transient gaps roughly four to six micrometers wide form at the junction when a leukocyte arrives, and those gaps close again within about five minutes once the cell has passed through. Some transmigration even happens at pre-existing gaps in VE-cadherin distribution that were already present before any immune cell showed up.⁴

The key finding from these studies is that the junction is remodeled, not destroyed. VE-cadherin gets displaced laterally and then diffuses back into position once the immune cell is through. This explains how millions of white blood cells can exit the bloodstream every day during an infection without the vessel wall falling apart. The gatekeeper steps aside for authorized visitors and then steps back.

A Built-In Flow Sensor

Blood constantly pushes against the inner surface of vessels, and endothelial cells need to detect that mechanical force to keep the vessel healthy. VE-cadherin is part of a sensory complex that does exactly this. Working together with two other junctional proteins, PECAM-1 and the growth factor receptor VEGFR2, VE-cadherin helps translate the physical push of flowing blood into chemical signals inside the cell.

Researchers measured this using molecular tension sensors built into VE-cadherin itself. Under static, no-flow conditions, VE-cadherin at cell-cell junctions bears significant tension generated by the cell’s own internal contractile machinery. When fluid shear stress begins, something counterintuitive happens: tension on VE-cadherin drops rapidly, within about thirty seconds, while tension on the neighboring protein PECAM-1 increases.⁵ This rapid shift in mechanical load between two junctional proteins is thought to be the triggering event that tells the cell “blood is flowing,” setting off downstream signaling cascades that keep the vessel aligned and healthy.⁶

This mechanosensory role helps explain why vessel disease tends to strike at branch points and curves, where the pattern of blood flow is disturbed. In those regions, the normal tension dynamics across VE-cadherin are altered, and the protective signaling pathways may not be properly activated.

Why Embryos Cannot Form Blood Vessels Without It

The most dramatic evidence for VE-cadherin’s importance comes from embryonic development. When researchers knocked out the VE-cadherin gene in mouse embryos, the initial assembly of endothelial cells into primitive vessel networks proceeded normally. But those networks could not remodel or mature into functional blood vessels, and the embryos died at about nine and a half days of gestation.⁷

The reason goes beyond simple adhesion. VE-cadherin turned out to be essential for transmitting a survival signal from VEGF, the main growth factor that keeps endothelial cells alive and proliferating. Without VE-cadherin, or when its intracellular tail was truncated so it could no longer bind beta-catenin, the survival signal could not reach the downstream enzymes that protect cells from programmed death. Endothelial cells in these embryos underwent apoptosis at high rates.⁷ So VE-cadherin is not merely a passive zipper. It actively participates in keeping endothelial cells alive by serving as a platform that brings growth factor receptors and signaling molecules into the right position.

In adult life, new blood vessels still sprout during wound healing and in growing tumors. During this sprouting process, VE-cadherin junctions are highly dynamic. At the tips and poles of migrating endothelial cells, large overlapping protrusions form that are driven by actin polymerization, and these structures actively remodel junctions to allow cells to rearrange as the new vessel extends. Blocking the actin-branching machinery at these sites reduced cell migration speed to roughly a quarter of normal values in laboratory sprouting models.⁸

When the Gatekeeper Breaks Down

If VE-cadherin is the molecule that keeps fluid inside blood vessels, then diseases characterized by massive fluid leakage should involve VE-cadherin disruption. They do. Sepsis and acute respiratory distress syndrome (ARDS) are two of the clearest examples.

In lung tissue from patients who died of sepsis-induced ARDS, VE-cadherin expression was significantly reduced across all vessel types compared with control tissue. Cell cultures that mimicked ARDS conditions confirmed the same pattern of disrupted borders and reduced VE-cadherin.⁹ The mechanism behind this loss has been traced in part to lactate, the same molecule that builds up in your muscles during intense exercise. During sepsis, blood lactate levels soar, and research has shown that lactate triggers an enzyme cascade that physically chops VE-cadherin apart. Specifically, lactate activates enzymes called calpains that cut VE-cadherin, and the chopped fragments are then pulled inside the cell, stripping it from the junction.¹⁰

The result is catastrophic vascular leakage: plasma floods into the lungs, and organ function collapses. Understanding this pathway matters because it suggests specific intervention points. If you could block the enzymes that degrade VE-cadherin, or stabilize its presence at junctions, you might limit the vascular leak that drives much of sepsis mortality.

How Tumors Exploit and Imitate VE-Cadherin

Cancer interacts with VE-cadherin in at least two distinct ways. First, when tumor cells metastasize, they must cross the blood vessel wall to colonize distant organs. This extravasation requires breaking the endothelial barrier, and research has shown that metastatic melanoma cells trigger VE-cadherin disassembly in endothelial cells through a signaling pathway involving the enzyme Src. The tumor cells essentially force the gatekeeper open.¹¹

The second interaction is stranger. Some highly aggressive tumor cells start producing VE-cadherin themselves, even though they are not endothelial cells. In aggressive melanoma, VE-cadherin expression was found exclusively in the most dangerous cell lines and was absent in less aggressive ones. When researchers knocked down VE-cadherin in these aggressive cells, the tumor cells lost their ability to form vessel-like networks, a phenomenon called vasculogenic mimicry, in which cancer cells create their own pseudo-vascular channels to supply themselves with blood.¹²

This mimicry appears to be driven by low-oxygen conditions inside tumors. Under hypoxia, a transcription factor called HIF-1-alpha ramps up VE-cadherin expression in tumor cells, promoting the formation of these pseudo-vascular channels. The effect has been documented in melanoma and in esophageal carcinoma, where silencing HIF-1-alpha both reduced VE-cadherin levels and blocked the formation of tubular networks.¹³ The overexpression of the anti-death protein Bcl-2 has also been shown to boost VE-cadherin and promote this mimicry even under normal oxygen conditions.¹⁴ The implication is that aggressive cancers may partly revert to an embryonic-like program, hijacking a molecule that normally belongs only to blood vessels.

VE-Cadherin Is Constantly Being Recycled

You might picture adherens junctions as static welds, but they are anything but. VE-cadherin molecules are constantly being pulled off the cell surface, sorted inside the cell, and shuttled back to the junction. This cycle of internalization and recycling is what gives junctions their ability to rapidly remodel in response to changing conditions.

The internalization is controlled by a specific region on VE-cadherin’s cytoplasmic tail that acts as an endocytic signal, essentially a “pull me inside” tag. Under normal conditions, a partner protein called p120-catenin sits on top of this tag, masking it and keeping VE-cadherin at the surface. When p120 detaches, the tag is exposed and VE-cadherin gets internalized. This design allows the cell to fine-tune how much VE-cadherin sits at junctions without having to make new protein from scratch every time.¹⁵

Once inside the cell, VE-cadherin enters early endosomes, sorting compartments that decide whether internalized cargo gets recycled back to the surface or routed to lysosomes for destruction. The recycling route depends on the protein Rab11a. When researchers silenced Rab11a in endothelial cells, VE-cadherin could not return to the plasma membrane, and it accumulated inside the cell, weakening the barrier.¹⁶ Another adaptor protein, p18, enhances this recycling and has been shown to protect the lung endothelial barrier in models of acute lung injury.¹⁷

This recycling system is also a vulnerability. Pathogens have evolved ways to hijack it. The Kaposi sarcoma-associated herpesvirus, for instance, produces a ubiquitin ligase called K5 that tags VE-cadherin for degradation rather than recycling, breaking down the endothelial barrier to the virus’s advantage.¹⁵

Aging Blood Vessels and Leaky Junctions

Vascular function declines with age, and VE-cadherin appears to be directly involved. Studies in aged rats found that VE-cadherin at arterial junctions was thinner and less intense compared with younger animals, and the arteries showed areas of severe endothelial thinning and disrupted junctions. The underlying mechanism involves increased phosphorylation of VE-cadherin by the enzyme Src, which promotes its internalization and degradation. In aged arteries, a smaller breakdown fragment of VE-cadherin accumulated, reflecting this accelerated turnover. The functional consequence was impaired vasodilation: old arteries responded more poorly to signals that should relax blood vessels.¹⁸¹⁹

The connection extends to the brain. In mouse models of Alzheimer’s disease, senescent endothelial cells showed altered VE-cadherin expression, failed to form proper junctions, and allowed increased permeability. These senescent cells were found precisely at sites of blood-brain barrier breakdown, where both VE-cadherin and another tight-junction protein, claudin-5, were decreased.²⁰ This finding raises the possibility that age-related VE-cadherin degradation contributes to the blood-brain barrier leakiness observed in neurodegenerative diseases, a hypothesis gaining more attention as researchers look beyond neurons and toward the vasculature for early disease mechanisms.

Measuring VE-Cadherin as a Clinical Biomarker

When VE-cadherin is cleaved from the endothelial surface, fragments are released into the blood. These soluble fragments can be measured, and elevated levels have been explored as a biomarker for endothelial damage across a range of diseases. A systematic review covering multiple human studies found that increased levels of soluble VE-cadherin, as well as autoantibodies against VE-cadherin, could serve as promising markers of endothelial dysfunction.²¹

In more specific clinical contexts, elevated soluble VE-cadherin has been measured in patients with hemolytic uremic syndrome caused by a particular bacterial infection, where it appeared to reflect the degree of endothelial injury.²² The appeal of a VE-cadherin blood test is that it would measure something the current standard of care cannot easily capture: the real-time integrity of the endothelial barrier. Existing markers of vascular damage tend to be indirect, and a direct readout of junction breakdown could help clinicians identify early vascular injury in sepsis, transplant rejection, or autoimmune vasculitis before organ damage becomes irreversible. The field is still early, though, and no VE-cadherin assay has become a routine clinical test.

VE-Cadherin Versus Other Cadherins in the Vessel Wall

Endothelial cells do not rely on VE-cadherin alone. They also express N-cadherin, a related adhesion molecule found in many cell types including neurons and smooth muscle cells. But the two cadherins occupy different locations and serve different purposes. VE-cadherin concentrates at cell-cell junctions between endothelial cells, where it mediates their direct contact with each other. N-cadherin, by contrast, is largely excluded from these junctions when VE-cadherin is present, and instead appears to mediate the connection between endothelial cells and the smooth muscle cells or pericytes that wrap around vessels from the outside.²³

This competition is not trivial. When VE-cadherin is experimentally removed or reduced, N-cadherin moves into the junctions, but it does not fully compensate. The specificity of VE-cadherin for the endothelial barrier appears to be irreplaceable. The distinction matters clinically because therapeutic strategies that target cadherins broadly, rather than VE-cadherin specifically, could inadvertently weaken the smooth-muscle-to-endothelium connections that rely on N-cadherin for structural support.

Signaling Crossroads and Partial Identity Shifts

The signaling that controls junction opening and closing is mediated in large part by a family of molecular switches called Rho GTPases. Different members of this family have opposing effects: some promote junction tightening while others drive junction opening, and the outcome depends on which switches are active and where in the cell they are located.²⁴ Computational modeling of this system has suggested that moderate contractile tension actually stabilizes VE-cadherin bonds within junctions, but that excessive contraction can pull junctions apart. Similarly, the signals that drive actin growth to help close gaps can, at high levels, weaken junctions instead.²⁵ The picture that emerges is one of a finely balanced system where too much or too little of any one signal can flip the junction from stable to leaky.

Under chronic disturbed flow, endothelial cells can undergo a partial identity shift toward a more mesenchymal, fibroblast-like state. This process, called endothelial-to-mesenchymal transition, involves gaining mesenchymal markers. One might expect VE-cadherin to drop during this shift, and a full transition does involve VE-cadherin loss. But experiments exposing endothelial cells to low-shear-stress conditions found that while mesenchymal markers appeared, VE-cadherin protein levels did not actually decrease. The transition was partial: the cells picked up some fibroblast characteristics without fully abandoning their endothelial identity.²⁶ This incomplete transition is thought to be relevant in atherosclerosis, where endothelial cells in disturbed-flow regions show mixed identities and compromised barrier function even without completely shedding VE-cadherin.

Toward Therapies That Stabilize the Gate

If so many diseases involve VE-cadherin disruption, the logical therapeutic question is whether you can hold it in place. Researchers have developed a cyclic peptide that mimics the external binding region of VE-cadherin and acts as a molecular cross-bridge, reinforcing the strand-swap connection between neighboring cells. In laboratory and animal models, this peptide stabilized VE-cadherin adhesion and reduced vascular hyperpermeability.²⁷ The concept is appealing because it targets the problem at its source: rather than mopping up leaked fluid or dampening downstream inflammation, a barrier-stabilizing agent would prevent the leak in the first place.

Other approaches focus on the recycling pathway. Boosting the proteins that return VE-cadherin to the cell surface, or blocking the enzymes that degrade it, could maintain barrier integrity during sepsis or acute lung injury. The adaptor protein p18, for example, enhanced VE-cadherin recycling and protected lung barriers in experimental models of injury.¹⁷ None of these strategies has reached routine clinical use, but they represent a shift in thinking: from treating the consequences of vascular leak to reinforcing the molecular gatekeeper that prevents it.